Informationen:
Fehler:
ID
41200
Beschreibung
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe); ODM derived from: https://clinicaltrials.gov/show/NCT01056510
Link
https://clinicaltrials.gov/show/NCT01056510
Stichworte
Versionen (1)
- 11.07.20 11.07.20 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
11. Juli 2020
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Lymphocytic Leukemia, Chronic NCT01056510
Eligibility Lymphocytic Leukemia, Chronic NCT01056510
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Lymphocytic Leukemia, Chronic NCT01056510
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Adult | Age
Item
adult patients, >/=18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Chronic Lymphocytic Leukemia
Item
chronic lymphocytic leukemia
boolean
C0023434 (UMLS CUI [1])
Chronic Lymphocytic Leukemia Binet Staging System
Item
active cll with progressive binet stage b or c
boolean
C0023434 (UMLS CUI [1,1])
C1511118 (UMLS CUI [1,2])
C1511118 (UMLS CUI [1,2])
Patient Ineligible Fludarabine
Item
ineligible for treatment with fludarabine
boolean
C0030705 (UMLS CUI [1,1])
C1512714 (UMLS CUI [1,2])
C0059985 (UMLS CUI [1,3])
C1512714 (UMLS CUI [1,2])
C0059985 (UMLS CUI [1,3])
Second line treatment | Pretreatment Rituximab | Pretreatment Chlorambucil
Item
for second line patients, only pretreatment with rituximab and/or chlorambucil is allowed
boolean
C1710038 (UMLS CUI [1])
C3539076 (UMLS CUI [2,1])
C0393022 (UMLS CUI [2,2])
C3539076 (UMLS CUI [3,1])
C0008163 (UMLS CUI [3,2])
C3539076 (UMLS CUI [2,1])
C0393022 (UMLS CUI [2,2])
C3539076 (UMLS CUI [3,1])
C0008163 (UMLS CUI [3,2])
ECOG performance status
Item
eocg performance status >/=2
boolean
C1520224 (UMLS CUI [1])
Recurrent disease | Status post Rituximab | Status post Chlorambucil First line treatment
Item
patients who have relapsed within <12 months of first dose of prior rituximab or chlorambucil first-line therapy
boolean
C0277556 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0393022 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C0008163 (UMLS CUI [3,2])
C1708063 (UMLS CUI [3,3])
C0231290 (UMLS CUI [2,1])
C0393022 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C0008163 (UMLS CUI [3,2])
C1708063 (UMLS CUI [3,3])
Stem cell transplant Previous | Stem cell transplant Planned
Item
previous or planned stem cell transplantation
boolean
C1504389 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C1504389 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
C0205156 (UMLS CUI [1,2])
C1504389 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Radioimmunotherapy
Item
radioimmunotherapy within 6 months prior to starting study treatment
boolean
C0085101 (UMLS CUI [1])
Transformation Aggressive malignancy B-cell
Item
transformation to aggressive b-cell malignancy
boolean
C0040682 (UMLS CUI [1,1])
C3149729 (UMLS CUI [1,2])
C0004561 (UMLS CUI [1,3])
C3149729 (UMLS CUI [1,2])
C0004561 (UMLS CUI [1,3])
Cancer treatment Other | Glucocorticoids | Prednisolone U/day | Equivalent
Item
any other concurrent anti-cancer therapy, or glucocorticoid >/=20mg daily prednisolone or equivalent
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0017710 (UMLS CUI [2])
C0032950 (UMLS CUI [3,1])
C0456683 (UMLS CUI [3,2])
C0205163 (UMLS CUI [4])
C0205394 (UMLS CUI [1,2])
C0017710 (UMLS CUI [2])
C0032950 (UMLS CUI [3,1])
C0456683 (UMLS CUI [3,2])
C0205163 (UMLS CUI [4])